Details for Patent: 9,403,799
Which drugs does patent 9,403,799 protect, and when does it expire?
Patent 9,403,799 protects TEPMETKO and is included in one NDA.
This patent has eighty patent family members in thirty-seven countries.
Summary for Patent: 9,403,799
| Title: | Pyrimidinyl-pyridazinone derivatives for treating a disease which is influenced by inhibition of met kinase |
| Abstract: | Compounds selected from the group according to claim 1 are inhibitors of tyrosine kinases, in particular of Met kinase, and can be employed, inter alia, for the treatment of tumors. |
| Inventor(s): | Oliver Schadt, Dieter Dorsch, Frank Stieber, Andree Blaukat |
| Assignee: | Merck Patent GmbH |
| Application Number: | US14/602,921 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; |
Drugs Protected by US Patent 9,403,799
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Emd Serono Inc | TEPMETKO | tepotinib hydrochloride | TABLET;ORAL | 214096-001 | Feb 3, 2021 | RX | Yes | Yes | 9,403,799 | ⤷ Start Trial | TREATING A SOLID TUMOR, INCLUDING LUNG CANCER, WITH A MET ALTERATION(S), OR STABILIZING OR IMPROVING SYMPTOMS ASSOCIATED WITH HAVING A SOLID TUMOR, INCLUDING LUNG CANCER, WITH A MET ALTERATION(S), BY ADMINISTERING AN EFFECTIVE AMOUNT OF TEPOTINIB | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,403,799
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2164843 | ⤷ Start Trial | C02164843/01 | Switzerland | ⤷ Start Trial |
| European Patent Office | 2164843 | ⤷ Start Trial | 301176 | Netherlands | ⤷ Start Trial |
| European Patent Office | 2164843 | ⤷ Start Trial | PA2022009 | Lithuania | ⤷ Start Trial |
| European Patent Office | 2164843 | ⤷ Start Trial | 2022C/519 | Belgium | ⤷ Start Trial |
| European Patent Office | 2164843 | ⤷ Start Trial | LUC00264 | Luxembourg | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
